Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia

Psychopharmacology

Volumn 225, Issue 3, 2013, Pages 627-635

  Ou, Jian Jun ^a   Xu, Yi ^b   Chen, Hong Hui ^c   Fan, Xiaoduo ^d   Gao, Keming ^e   Wang, Juan ^a   Guo, Xiao Feng ^a   Wu, Ren Rong ^a   Zhao, Jing Ping ^a,f  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANDONG MENTAL HEALTH CENTER   (China)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f The Hangzhou Seventh People Hospital   (China)

Author keywords

First episode schizophrenia; Metabolic effect; Olanzapine; Ziprasidone

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN; OLANZAPINE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FIRST EPISODE SCHIZOPHRENIA; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; FEMALE; GLUCOSE; HUMANS; INSULIN; LIPID METABOLISM; MALE; MIDDLE AGED; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES; YOUNG ADULT;

EID: 84873729944     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2850-6     Document Type: Article

References (29)

1. Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, El Tallawy H, Danaci AE, Lowe W, Karayal ON (2009) Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 24:229-238
2. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM (2005) Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 162:1879-1887
3. Brown RR, Estoup MW (2005) Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 20:105-112
4. Dossenbach M, Treuer T, Kryzhanovskaya L, Saylan M, Dominguez S, Huang X (2007) Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa. J Clin Psychopharmacol 27:329-337
5. Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR (2007) Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc: JAPhA 47:373-378
6. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15
7. Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, Verkes RJ, Kahn RS (2011) Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull 37:352-361
8. Henderson DC (2007) Weight gain with atypical antipsychotics: evidence and insights. J clin psychiatry 68(Suppl 12):18-26
9. Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219
10. Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM (2009) Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 150:474-484
11. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085-1097
12. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: CD006654
13. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S (2009) Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: CD006627
14. Law MR, Wald NJ (1994) An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr 48:305-325
15. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209-1222
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
17. Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA (2009) Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. world j biol psychiatry: off j World Fed Soc Biol Psychiatry 10:710-718
18. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32
19. Miller BJ, Paschall CB, Svendsen DP (2006) Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 57:1482-1487
20. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56:1113-1132
21. Olsson AG (2010) HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin. Nutr Metab Cardiovasc Dis 20:553-557
22. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, Davis JM, Leucht S (2012) Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 38:167-177
23. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225-233
24. Sachs GS, Guille C (1999) Weight gain associated with use of psychotropic medications. J clin psychiatry 60(Suppl 21):16-19
25. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004) Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161:1837-1847
26. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ (2005) Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 162:1535-1538
27. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM (2011) Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 168:193-201
28. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620-627
29. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495